Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2248 articles about Gilead Sciences, Inc.
-
Gilead Sciences, Inc. Plans 1,900 New Jobs; Biotech Company Moves to Double Foster City Headquarters
8/25/2008
-
Gilead Sciences, Inc. AIDS Drugs Will Be Tested To See If They Can Prevent HIV
8/4/2008
-
Richard J. Whitley, MD Joins Gilead Sciences, Inc.'s Board of Directors
7/31/2008
-
Gilead Sciences, Inc. Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV
7/23/2008
-
Gilead Sciences, Inc. Announces Second Quarter 2008 Financial Results
7/18/2008
-
Gilead Sciences, Inc. to Release Second Quarter 2008 Financial Results on Thursday, July 17, 2008
7/9/2008
-
Monogram Biosciences Collaborates with Gilead Sciences, Inc. for Elvitegravir
6/18/2008
-
Gilead Sciences, Inc. Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis; Aztreonam Lysine Well Tolerated
6/13/2008
-
Gilead Sciences, Inc. to Present at the 29th Annual Goldman, Sachs & Co. Global Healthcare Conference on Wednesday, June 11
6/5/2008
-
Boehringer Ingelheim Corporation, Gilead Sciences, Inc. Agree to AIDS Drug Price Freeze
6/3/2008
-
Gilead Sciences, Inc. Release: U.S. Patent Office Confirms Second of Four Viread® Patents
6/2/2008
-
Gilead Sciences, Inc. and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension
5/30/2008
-
Data from Pivotal Phase III Studies of Gilead Sciences, Inc.'s Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension Published
5/29/2008
-
Gilead Sciences, Inc.' Chairman and Chief Executive Officer Establishes Rule 10b5-1 Stock Trading Plan
5/23/2008
-
Gilead Sciences, Inc. Says U.S. Upholds One Viread Patent
5/21/2008
-
Gilead Sciences, Inc. Release: U.S. Patent Office Confirms First of Four Viread(R) Patents
5/21/2008
-
Gilead Announces New Letairis(R) (Ambrisentan) Data for the Treatment of Patients With Pulmonary Arterial Hypertension (WHO Group 1) With WHO Functional Class II or III Symptoms
5/20/2008
-
Gilead Sciences, Inc. to Present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21
5/15/2008
-
Gilead Sciences, Inc.' Board Member Establishes Rule 10b5-1 Stock Trading Plan
5/14/2008
-
Gilead Sciences, Inc. to Present at the Bank of America 2008 Healthcare Conference on Tuesday, May 13
5/12/2008